• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Galapagos Announces Executive Leadership Updates

    4/21/25 4:10:00 PM ET
    $GLPG
    $NMRA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $GLPG alert in real time by email

    Mr. Henry Gosebruch appointed by the Galapagos Board of Directors as founding CEO of newly created SpinCo 

    Dr. Paul Stoffels, Chair and CEO of Galapagos, plans to retire as CEO upon appointment of successor in the next 12 months and plans to continue as Chair of the Board of Directors, ensuring leadership continuity and long-term strategic guidance

    Mechelen, Belgium; April 21, 2025, 22:10 CET; regulated information – inside information – Galapagos NV ((Euronext &, NASDAQ:GLPG), a global biotechnology company dedicated to transforming patient outcomes through life-changing science and innovation, today makes two executive leadership announcements.

    In line with its planned separation into two independent entities (the "Separation"), Mr. Henry Gosebruch was today appointed as founding CEO of the Galapagos subsidiary, currently named XYZ SpinCo NV ("SpinCo"), which will be renamed in the Separation. As previously disclosed, SpinCo will separate from Galapagos' current operations and initially be funded with approximately €2.45 billion in cash and cash equivalents. SpinCo will be focused on building a pipeline of innovative medicines with demonstrated proof-of-concept and the potential to elevate standard-of-care for patients through one or more transformative transactions. In parallel, Galapagos will continue to advance its pipeline of potential best-in-class cell therapies in hematological and solid tumors, leveraging its foundational decentralized manufacturing platform.

    Dr. Stoffels1, CEO and Chair of the Board of Directors at Galapagos, commented, "Henry's appointment marks a key milestone as we progress on our planned Separation. His extensive biotech experience, leadership, and track record in creating shareholder value through M&A and business development will be of significant value to SpinCo, as it focuses on building a differentiated pipeline of innovative medicines with robust proof-of-concept."

    Henry Gosebruch, incoming CEO of SpinCo, commented, "I am honored to take on the role of Founding CEO of SpinCo. I look forward to forming a world-class team and pursuing transformational opportunities in innovative medicines that can bring meaningful therapies to patients in need, while unlocking significant value for our shareholders."

    "Henry is the right leader to take on the CEO role for SpinCo as he leverages his extensive experience and the strong balance sheet to build an exciting pipeline," said Mr. Andrew Dickinson, Chief Financial Officer, Gilead Sciences, and Non-Executive Non-Independent Member, Galapagos' Board of Directors. "We look forward to working with him as he pursues transactions with the potential to create significant value for all shareholders."

    Dr. Stoffels, Chair and CEO of Galapagos, has informed the Board of Directors of his intent to retire from his role as CEO upon appointment of a successor, and to remain as Non-Executive Chair of the Galapagos Board of Directors, thereby being able to continue to provide strategic guidance and support to the Company, subject to the reappointment as Director at the 2026 Annual General Meeting. The Board will search for a successor CEO who will lead Galapagos into its next phase of growth and innovation as a focused cell therapy company, dedicated to delivering breakthrough treatments that address high unmet patient need.  The successor CEO is expected to be hired in the next 12 months.

    Dr. Stoffels said, "I am proud to have transformed Galapagos into an R&D-driven biotech company with a clear focus on oncology. Following the acquisitions of CellPoint and Abound Bio in 2022, we established a unique decentralized manufacturing platform designed to deliver fresh, stem-like early memory cell therapy with a vein-to-vein time of just seven days. Two programs leveraging this platform are currently in Phase 2 clinical studies targeting nine aggressive hematological malignancies, a TCR-T candidate having delivered strong preclinical proof-of-concept in solid tumors, and a next-generation CAR-T candidate expected to enter the clinic by year-end. With the Separation, Galapagos will have the autonomy to execute on its cell therapy growth strategy, focusing on advancing its pipeline of potentially best-in-class assets and building a global, decentralized manufacturing network."

    "On behalf of the Board, I would like to sincerely thank Paul for reshaping Galapagos' strategy over the past three years. His leadership has helped sharpen our focus on developing new oncology treatments, making meaningful progress for patients while creating long-term value for shareholders. Looking ahead, the Board intends to propose Paul for a second four-year term as Director at the 2026 Annual General Meeting and to have him continue as Chair of the Board, thereby staying closely involved with the Company," said Mr. Jérôme Contamine, Lead Non-Executive Director of Galapagos. "Having worked closely with Henry on successful M&A in the past, I am delighted to welcome him to Galapagos. I have great confidence that Henry has the appropriate skills to lead SpinCo as it embarks on its mission."

    Background information on Mr. Gosebruch

    Mr. Gosebruch joins SpinCo with deep experience in M&A, business development, partnering and venture capital, and a strong track record of building new growth businesses, pursuing pipeline opportunities, prudent capital allocation and creating shareholder value.

    Mr. Gosebruch was most recently President and Chief Executive Officer at Neumora (NASDAQ:NMRA), a clinical-stage biopharmaceutical company focused on redefining neuroscience drug development. He joined Neumora in July 2023, leading the company through its initial public offering (IPO) in September 2023 and advancing its capabilities and pipeline.

    Prior to Neumora, Mr. Gosebruch was Executive Vice President and Chief Strategy Officer at AbbVie, where he was responsible for Corporate Strategy, Competitive Strategy & Insights, Business Development & Acquisitions, Search & Evaluation, Alliance Management, R&D decision support/portfolio analytics and AbbVie Ventures. At AbbVie, Mr. Gosebruch and his team completed more than 100 business development transactions, diversifying AbbVie by building new growth businesses and pipeline opportunities. Among others, Mr. Gosebruch and his team played a critical role in identifying and executing the acquisition of Allergan and the partnership for risankizumab (Skyrizi®).

    Prior to joining AbbVie in 2015, Mr. Gosebruch worked at J.P. Morgan for more than 20 years, most recently as its North American M&A Group Co-Head based in New York. During his time at J.P. Morgan, Mr. Gosebruch worked on M&A transactions in excess of $375 billion in total value involving companies in more than 20 countries.

    About Galapagos

    We are a biotechnology company with operations in Europe and the U.S. dedicated to transforming patient outcomes through life-changing science and innovation for more years of life and quality of life. Focusing on high unmet medical needs, we synergize compelling science, technology, and collaborative approaches to create a deep pipeline of best-in-class medicines. With capabilities from lab to patient, including a decentralized cell therapy manufacturing platform, we are committed to challenging the status quo and delivering results for our patients, employees, and shareholders. Our goal is not just to meet current medical needs but to anticipate and shape the future of healthcare, ensuring that our innovations reach those who need them most. For additional information, please visit www.glpg.com or follow us on LinkedIn or X.

    This press release contains inside information within the meaning of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse (market abuse regulation).

    For further information, please contact:

    Media inquiries:

    Srikant Ramaswami

    +1 412 699 0359



     



    Marieke Vermeersch

    +32 479 490 603



     



    [email protected]
    Investor inquiries:

    Srikant Ramaswami

    +1 412 699 0359



     



    Glenn Schulman

    +1 412 522 6239



     



    [email protected]

    Forward-looking statements

    This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. These statements are often, but are not always, made through the use of words or phrases such as "anticipate," "expect," "plan," "estimate," "will," "continue," "aim," "intend," "future," "potential," "could," "indicate," "forward," as well as similar expressions. Forward-looking statements contained in this release include, but are not limited to, statements regarding hiring of key personnel, statements regarding the intended Separation of Galapagos into two independent entities and related transactions, including the expected timeline of such transactions, anticipated changes to the management and Board of Directors of each of Galapagos and SpinCo, the anticipated benefits and synergies of such transactions and the receipt of regulatory and shareholder approvals for such transactions, and statements regarding the search for and announcement of a suitable successor for the Galapagos' CEO. Forward-looking statements involve known and unknown risks, uncertainties and other factors which might cause Galapagos' actual results to be materially different from those expressed or implied by such forward-looking statements. These risks, uncertainties and other factors include, without limitation, the possibility that Galapagos and SpinCo will encounter challenges retaining or attracting talent, that the CEO appointment may be disruptive to our or SpinCo's (future) business operations, risks related to our ability to effectively transfer knowledge, the risks related to the search and recruitment of a suitable successor for our Galapagos' CEO, the risks associated with the anticipated transactions, including the risk that regulatory and shareholder approvals required in connection with the transactions will not be received or obtained within the expected time frame or at all, the risk that the transactions and/or the necessary conditions to consummate the transactions will not be satisfied on a timely basis or at all, uncertainties regarding our ability to successfully separate Galapagos into two independent entities and realize the anticipated benefits from the Separation within the expected time frame or at all, the two separate entities' ability to succeed as stand-alone, publicly traded companies, as well as those risks and uncertainties identified in Galapagos' Annual Report on Form 20-F for the year ended 31 December 2024 filed with the U.S. Securities and Exchange Commission (SEC) and its subsequent filings with the SEC. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. The forward-looking statements contained herein are based on management's current expectations and beliefs and speak only as of the date hereof, and Galapagos makes no commitment to update or publicly release any revisions to forward-looking statements in order to reflect new information or subsequent events, circumstances, or changes in expectations.


    1 Throughout this press release, ‘Dr. Paul Stoffels' should be read as ‘Dr. Paul Stoffels, acting via Stoffels IMC BV'.

    Attachment

    • GLPG Press Release _Executive Leadership Updates_250421_ENG


    Primary Logo

    Get the next $GLPG alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $GLPG
    $NMRA

    CompanyDatePrice TargetRatingAnalyst
    Neumora Therapeutics Inc.
    $NMRA
    4/2/2025$1.00Buy → Underperform
    BofA Securities
    Neumora Therapeutics Inc.
    $NMRA
    3/10/2025Outperform → Mkt Perform
    William Blair
    Neumora Therapeutics Inc.
    $NMRA
    3/7/2025Buy → Neutral
    Guggenheim
    Neumora Therapeutics Inc.
    $NMRA
    3/7/2025$6.00 → $2.00Buy → Hold
    Stifel
    Galapagos NV
    $GLPG
    2/14/2025$31.00 → $22.00Equal-Weight → Underweight
    Morgan Stanley
    Neumora Therapeutics Inc.
    $NMRA
    1/2/2025$29.00 → $4.00Outperform → Sector Perform
    RBC Capital Mkts
    Galapagos NV
    $GLPG
    11/20/2024Hold → Reduce
    Kepler
    Neumora Therapeutics Inc.
    $NMRA
    11/5/2024$18.00 → $15.00Overweight → Neutral
    JP Morgan
    More analyst ratings

    $GLPG
    $NMRA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Galapagos Announces Oral Presentations at EHA and ICML 2025 Featuring Promising New Data from ATALANTA-1 study of Investigational CAR-T Candidate GLPG5101

      Mechelen, Belgium; May 14, 2025, 22:01 CET; Galapagos NV ((Euronext &, NASDAQ:GLPG), a global biotechnology company dedicated to transforming patient outcomes through life-changing science and innovation, today announced that new data from our ongoing ATALANTA-1 Phase 1/2 study of GLPG5101 in relapsed/refractory non-Hodgkin lymphoma (R/R NHL) have been accepted for oral presentations at the 2025 European Hematology Association (EHA) Congress taking place June 12-15, 2025, in Milan, Italy, and the International Conference on Malignant Lymphoma (ICML) in Lugano, Switzerland the following week. "At Galapagos, we are driven by a mission to expand access to transformative cell therapies for pa

      5/14/25 4:01:00 PM ET
      $GLPG
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Galapagos Announces Strategic Update on Proposed Separation, Executive Leadership Transition and Board Changes

      Galapagos to re-evaluate the implementation of the previously announced separation following regulatory and market developments Galapagos to explore all strategic alternatives for its existing businesses, including cell therapy, with a focus on maximizing resources available for transformative business development transactions Mr. Henry Gosebruch appointed by the Galapagos Board of Directors as CEO of Galapagos, effective immediately, succeeding Dr. Paul Stoffels who announced his retirement in April 2025 Mr. Jérôme Contamine, formerly Lead Non-Executive Director, has been appointed Chair of the Board of Directors of Galapagos, replacing Dr. Paul Stoffels Mechelen, Belgium; May 13, 2025,

      5/13/25 1:35:49 AM ET
      $GLPG
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Neumora Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

      On track to report topline data from NMRA-511 in Alzheimer's disease agitation around the end of 2025 Resumed enrollment for KOASTAL-3 and -2 studies in March 2025; anticipate reporting topline major depressive disorder data from KOASTAL-3 in the first quarter of 2026 and -2 in the second quarter of 2026 Expect to progress M4 positive allosteric modulator (PAM) program into the clinic in mid-2025 Secured $125 million venture debt facility from K2 HealthVentures, with $40 million available in 2025; cash runway extended into 2027 Company to host conference call today at 4:30 p.m. ET WATERTOWN, Mass., May 12, 2025 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (NASDAQ:NMRA) a clinical-s

      5/12/25 4:01:00 PM ET
      $NMRA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $GLPG
    $NMRA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by Neumora Therapeutics Inc.

      SC 13D/A - Neumora Therapeutics, Inc. (0001885522) (Subject)

      11/22/24 5:33:43 PM ET
      $NMRA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed by Neumora Therapeutics Inc.

      SC 13G - Neumora Therapeutics, Inc. (0001885522) (Subject)

      11/12/24 4:30:30 PM ET
      $NMRA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Galapagos NV

      SC 13G/A - GALAPAGOS NV (0001421876) (Subject)

      11/12/24 9:55:16 AM ET
      $GLPG
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GLPG
    $NMRA
    Financials

    Live finance-specific insights

    See more
    • Neumora Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

      On track to report topline data from NMRA-511 in Alzheimer's disease agitation around the end of 2025 Resumed enrollment for KOASTAL-3 and -2 studies in March 2025; anticipate reporting topline major depressive disorder data from KOASTAL-3 in the first quarter of 2026 and -2 in the second quarter of 2026 Expect to progress M4 positive allosteric modulator (PAM) program into the clinic in mid-2025 Secured $125 million venture debt facility from K2 HealthVentures, with $40 million available in 2025; cash runway extended into 2027 Company to host conference call today at 4:30 p.m. ET WATERTOWN, Mass., May 12, 2025 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (NASDAQ:NMRA) a clinical-s

      5/12/25 4:01:00 PM ET
      $NMRA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Neumora Therapeutics to Report First Quarter 2025 Financial Results on Monday, May 12, 2025

      WATERTOWN, Mass., April 28, 2025 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (NASDAQ:NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of seven brain disease programs including two clinical-stage programs, today announced that it will host a conference call and live webcast at 4:30 p.m. ET on Monday, May 12, 2025 to report its first quarter 2025 financial results and provide a business update. A live webcast of the event will be available on the events and presentations section of the Company's website at www.neumoratx.com. A replay of the webcast will be available following the completion of the event and will be archived for up to 30 days. Part

      4/28/25 7:00:00 AM ET
      $NMRA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Galapagos Reports First Quarter 2025 Financial Results, Recent Business Highlights and Near-Term Catalysts

      First U.S. patient dosed in ATALANTA-1 study of GLPG5101 Mantle cell lymphoma (MCL), a high-unmet-need hematological malignancy, selected as lead indication for the GLPG5101 program; Pivotal development planned to start in 2026 and aiming for approval in 2028 Executive leadership changes with Dr. Paul Stoffels retiring as CEO upon appointment of his successor while continuing as Chair of the Board, Thad Huston departing as CFO/COO on August 1, 2025, and Henry Gosebruch appointed Founding CEO of Galapagos subsidiary SpinCo €3.3 billion in cash and financial investments as of March 31, 2025; Normalized annual cash burn guidance, excluding restructuring costs, in the range of €175 million -

      4/23/25 4:01:00 PM ET
      $GLPG
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GLPG
    $NMRA
    SEC Filings

    See more
    • SEC Form DEFA14A filed by Neumora Therapeutics Inc.

      DEFA14A - Neumora Therapeutics, Inc. (0001885522) (Filer)

      5/16/25 4:28:34 PM ET
      $NMRA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 8-K filed by Neumora Therapeutics Inc.

      8-K - Neumora Therapeutics, Inc. (0001885522) (Filer)

      5/16/25 4:26:52 PM ET
      $NMRA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 6-K filed by Galapagos NV

      6-K - GALAPAGOS NV (0001421876) (Filer)

      5/14/25 4:43:47 PM ET
      $GLPG
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GLPG
    $NMRA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Officer Berns Paul L sold $23,468 worth of shares (13,871 units at $1.69), decreasing direct ownership by 0.19% to 7,405,004 units (SEC Form 4)

      4 - Neumora Therapeutics, Inc. (0001885522) (Issuer)

      2/20/25 5:14:53 PM ET
      $NMRA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Officer Milligan Michael Lee sold $3,351 worth of shares (1,978 units at $1.69), decreasing direct ownership by 8% to 22,470 units (SEC Form 4)

      4 - Neumora Therapeutics, Inc. (0001885522) (Issuer)

      2/20/25 5:14:01 PM ET
      $NMRA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Chief Strategy Officer Aurora Daljit Singh sold $14,347 worth of shares (8,565 units at $1.68), decreasing direct ownership by 9% to 88,935 units (SEC Form 4)

      4 - Neumora Therapeutics, Inc. (0001885522) (Issuer)

      2/20/25 5:13:14 PM ET
      $NMRA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $GLPG
    $NMRA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Neumora Therapeutics downgraded by BofA Securities with a new price target

      BofA Securities downgraded Neumora Therapeutics from Buy to Underperform and set a new price target of $1.00

      4/2/25 8:47:48 AM ET
      $NMRA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Neumora Therapeutics downgraded by William Blair

      William Blair downgraded Neumora Therapeutics from Outperform to Mkt Perform

      3/10/25 7:56:32 AM ET
      $NMRA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Neumora Therapeutics downgraded by Guggenheim

      Guggenheim downgraded Neumora Therapeutics from Buy to Neutral

      3/7/25 8:22:06 AM ET
      $NMRA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $GLPG
    $NMRA
    Leadership Updates

    Live Leadership Updates

    See more
    • Galapagos Announces Strategic Update on Proposed Separation, Executive Leadership Transition and Board Changes

      Galapagos to re-evaluate the implementation of the previously announced separation following regulatory and market developments Galapagos to explore all strategic alternatives for its existing businesses, including cell therapy, with a focus on maximizing resources available for transformative business development transactions Mr. Henry Gosebruch appointed by the Galapagos Board of Directors as CEO of Galapagos, effective immediately, succeeding Dr. Paul Stoffels who announced his retirement in April 2025 Mr. Jérôme Contamine, formerly Lead Non-Executive Director, has been appointed Chair of the Board of Directors of Galapagos, replacing Dr. Paul Stoffels Mechelen, Belgium; May 13, 2025,

      5/13/25 1:35:49 AM ET
      $GLPG
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Galapagos Publishes 2024 Annual Report and Announces Annual Shareholders' Meeting

      Mechelen, Belgium; March 27, 2025, 21:01 CET; regulated information – Galapagos NV ((Euronext &, NASDAQ:GLPG) today publishes its annual report for the financial year 2024 and announces its Annual Shareholders' Meeting (AGM) to be held on Tuesday, April 29, 2025 at 14:00 CET at the registered office of the Company.  The annual report for the financial year 2024, including a review of figures and performance, is available online at https://www.glpg.com/financial-reports and can also be downloaded as PDF. The annual 2024 Form 20-F filing with the SEC is available at www.sec.gov/edgar. Galapagos has the honor to invite its shareholders, holders of subscription rights, Board members, and

      3/27/25 4:01:00 PM ET
      $GLPG
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Galapagos welcomes Oleg Nodelman to its Board of Directors to support strategic growth

      Mechelen, Belgium; October 7, 2024, 07:00 CET — Galapagos NV ((Euronext &, NASDAQ:GLPG), today announced the appointment by way of co-optation of Oleg Nodelman as Non-Executive Non-Independent Director to its Board of Directors, effective October 7, 2024. Mr. Nodelman replaces Mr. Dan G. Baker who stepped down on October 6, 2024. The addition of Mr. Nodelman marks an important step in Galapagos' ongoing efforts to engage with shareholders and continue to execute on our Forward, Faster strategy to accelerate innovation and create near-and long-term value.  "We are pleased to welcome Oleg Nodelman to the Galapagos Board," said Dr. Paul Stoffels, Galapagos' CEO and Chair of the Board of Direc

      10/7/24 1:00:00 AM ET
      $GLPG
      Biotechnology: Pharmaceutical Preparations
      Health Care